Bayer Gets EU Approval for Xarelto Treatment of Pulmonary Embolism

Date : 11/20/2012 @ 3:24AM
Source : Dow Jones News
Stock : Bayer AG NA O.N. (BAYN)
Quote : 107.75  -0.35 (-0.32%) @ 11:30AM
Bayer share price Chart

Bayer Gets EU Approval for Xarelto Treatment of Pulmonary Embolism

Bayer (XE:BAY001)
Historical Stock Chart

5 Years : From Nov 2012 to Nov 2017

Click Here for more Bayer Charts.

German chemical and pharmaceutical company Bayer AG (BAYN.XE) said Tuesday it has received European Commission approval for its Xarelto drug to prevent deep vein thrombosis and treat pulmonary embolism.


-Xarelto, also known as Rivaroxaban, is the only oral blood thinner approved for this indication within the European Union.

-Pulmonary embolism occurs when a blood clot in the deep veins of the leg or pelvis detaches and travels to the lung via the heart, where it can block one of the pulmonary arteries.

-Earlier this month, Bayer reiterated its estimate of peak sales potential above EUR2 billion for Xarelto.

-The Xarelto treatment resulted in significantly lower rates of major bleeding among patients in a phase III study.

-"As a new treatment option, rivaroxaban offers a single-drug solution that works as fast as injectable enoxaparin and can provide protection for as long as needed," Professor Harry Bueller of the Academic Medical Center in Amsterdam, who led the clinical trial program, said.

-Frankfurt Bureau, Dow Jones Newswires; 49-69-29725-500 

Subscribe to WSJ:

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V:us D:20171117 23:01:10